Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton Apr 07, 2021 11:54am
205 Views
Post# 32949486

RE:RE:Some calls about some things...

RE:RE:Some calls about some things...Thanks for that, chrispi. So now we have it. Bioasis has or is getting data that will be reported in due course. I confess that I don't read this forum in any great detail anymore, so I missed your comments on that. I wish that point was made clearer in the CP.

But that wasn't the purpose behind my previous post. Readers here need to understand that I do not represent the company. I am a commentator and I research, assess, and comment about things that are completely in the public domain, things like corporate presentations, financial reports, websites, scientific literature and pharmaceutical industry news. 

I am not an apologist for the company. I do not represent Bioasis. In my own poor way, I do the same things that the Edison Group, Zacks and other paid commentators do.

Herein lies the problem. I remain very supportive of the xB3 Platform. It has been tested dozens of times and it has never failed. I support Bioasis shareholders. I am a shareholder. My interests are the same as any other shareholder's. I remain appalled at the public behaviour of some shareholders, but generally, they speak the truth and I don't argue with them about the past failings of Bioasis. I have articulated those failures here and elsewhere. The failures were needless and cause me as much or more anger than they do any poster who whines on this forum.

But failures were then, not now. As far as I am concerned, hope started for Bioasis about two years ago with the appointment of Dr. Deborah Rathjen (DrDR) as CEO. The rebirth of Bioasis started about a year ago. That rebirth is completely the result of DrDR's very careful rebuilding of Bioasis. I have two posts coming out that will begin to explain the rebirth although I will not be using that word on my website. Bioasis needs to be completely in the present, in its programs and in its public optics.

I do not sit in my chair and fret, weep and rave about the past. I look at what we have today and I believe that what Bioasis has set out to do is explosive, disruptive and will bring immense value to shareholders if the science continues to stand.

DrDR deserves credit for this rebirth but as a professional, I suspect that she understands that you're only as good as the next all-time high of the share price. That's the game. From where I sit, that's where she and Bioasis are headed. Bioasis, if it continues to execute, will make the news and should make money for its shareholders.

About the phone calls and this forum, I don't and never have had any say in the development and execution of Bioasis plans. I wrote Bioasis press releases for years until Catherine London (Day) took that over. (And then I took over explaining her press releases on Stockhouse. Haha! Joke? Not really.) I came up with the xB3 name, but not the silly xB3-cubed name that never survives reformatting into plain text. The superscripting of the "3" should be abandoned. As branding, it is metaphorically meaningless. There are 3 Bs in BBB, not 3-cubed Bs in BBB. And as for artistic design qualities, it isn't artistic. But I have digressed.

I don't mind phonecalls in which Bioasis plans and activities are discussed. I don't mind hard questions. I love speculations about where Bioasis is going. I will discuss the past, to some degree, because the past explains what we are today.

But I will no longer tolerate 1 or 2-hour phone calls where I have to sit and listen to abusive language about the CEO and whining about having held the stock for 10 years and how awful things are and all of that. We're all in that boat. There's nothing special about any of you in that regard.  Honestly, I fail to understand why some of you cannot see what's going on with Bioasis. I'll explain it the best I can. You will get commentary from me that you will not find with my erstwhile competitors.

The company is on its way. It's time to let it play out. If it's too painful then step away. Sell your stock into the hands of those who want it. We all deserve not only peace but also the highs that can come from well-considered plans and expectations. In my opinion, well-considered plans and expectations are exactly what we have from Bioasis, right now.

jd
<< Previous
Bullboard Posts
Next >>